The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: A randomized clinical trial

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 172-180

  Hawk Jr , L W ^a   Ashare, R L ^a   Lohnes, S F ^a   Schlienz, N J ^a   Rhodes, J D ^a,b   Tiffany, S T ^a   Gass, J C ^a   Cummings, K M ^c,d   Mahoney, M C ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; PLACEBO; VARENICLINE;

ADULT; AGED; AMNESIA; ANOREXIA; ARTICLE; BLOATING; CIGARETTE SMOKING; COMPLIANCE (PHYSICAL); CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAM; DRUG WITHDRAWAL; EAR DISEASE; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; INDIGESTION; INSOMNIA; MALE; MOOD; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEX DIFFERENCE; SIDE EFFECT; SKIN DISEASE; SMOKING CESSATION; SMOKING HABIT; SUICIDAL BEHAVIOR; TASTE DISORDER; TOBACCO DEPENDENCE; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

BEHAVIOR, ADDICTIVE; BENZAZEPINES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SEX CHARACTERISTICS; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TOBACCO USE DISORDER;

EID: 84855935476     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.317     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2007. MMWR Morb. Mort. Wkly Rep. Vol. 57 1221-1226 (2008).
2. AF iore, M.C. et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. (US Department of Health and Human Service. Public Health Service, Rockville, MD, 2008).
3. Cahill, K., Stead, L.F. & Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. CD006103 (2011).
4. Lerman, C. et al. Translational research in medication development for nicotine dependence. Nat. Rev. Drug Discov. 6, 746-762 (2007). (Pubitemid 47338182)
5. Baker, T.B. et al. New methods for tobacco dependence treatment research. Ann. Behav. Med. 41, 192-207 (2011).
6. Mihalak, K.B., Carroll, F.I. & Luetje, C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 70, 801-805 (2006). (Pubitemid 44268437)
7. Gonzales, D. et al.; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296, 47-55 (2006).
8. Jorenby, D.E. et al.; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63 (2006).
9. Rose, J.E. & Levin, E.D. Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br. J. Addict. 86, 605-609 (1991).
10. Cummings, K.M. & Mahoney, M.C. Strategies for smoking cessation: what is new and what works? Expert Rev. Respir. Med. 2, 201-213 (2008). (Pubitemid 351982830)
11. O'Connor, E.C., Parker, D., Rollema, H. & Mead, A.N. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl.) 208, 365-376 (2010).
12. Rollema, H. et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52, 985-994 (2007). (Pubitemid 46227486)
13. Rose, J.E., Behm, F.M. & Westman, E.C. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp. Clin. Psychopharmacol. 6, 331-343 (1998). (Pubitemid 28393951)
14. Shiffman, S. & Ferguson, S.G. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 103, 557-563 (2008). (Pubitemid 351389280)
15. Benowitz, N.L. & Hatsukami, D. Gender differences in the pharmacology of nicotine addiction. Addict. Biol. 3, 383-404 (1998). (Pubitemid 28461408)
16. Perkins, K.A., Donny, E. & Caggiula, A.R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob. Res. 1, 301-315 (1999).
17. Cepeda-Benito, A., Reynoso, J.T. & Erath, S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J. Consult. Clin. Psychol. 72, 712-722 (2004). (Pubitemid 38988848)
18. Perkins, K.A. & Scott, J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob. Res. 10, 1245-1250 (2008).
19. Coe, J.W. et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474-3477 (2005). (Pubitemid 40664098)
20. Hajek, P., McRobbie, H.J., Myers, K.E., Stapleton, J. & Dhanji, A.R. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch. Intern. Med. 171, 770-777 (2011).
21. Shiffman, S., Stone, A.A. & Hufford, M.R. Ecological momentary assessment. Annu. Rev. Clin. Psychol. 4, 1-32 (2008). (Pubitemid 351688514)
22. Rose, J.E., Behm, F.M., Westman, E.C. & Kukovich, P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob. Res. 8, 89-101 (2006).
23. Rose, J.E. Nicotine preloading: the importance of a pre-cessation reduction in smoking behavior. Psychopharmacology (Berl), 1-2 (2011).
24. Benowitz, N.L. Nicotine addiction. N. Engl. J. Med. 362, 2295-2303 (2010).
25. Bouton, M.E., Westbrook, R.F., Corcoran, K.A. & Maren, S. Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol. Psychiatry 60, 352-360 (2006). (Pubitemid 44215847)
26. Bouton, M.E. Context and behavioral processes in extinction. Learn. Mem. 11, 485-494 (2004). (Pubitemid 39299694)
27. Bouton, M.E. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol. Psychiatry 52, 976-986 (2002). (Pubitemid 35356355)
28. Conklin, C.A. Environments as cues to smoke: implications for human extinction-based research and treatment. Exp. Clin. Psychopharmacol. 14, 12-19 (2006).
29. Conklin, C.A. & Tiffany, S.T. Applying extinction research and theory to cueexposure addiction treatments. Addiction 97, 155-167 (2002). (Pubitemid 34112374)
30. Poling, J., Rounsaville, B., Gonsai, K., Severino, K. & Sofuoglu, M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am. J. Addict. 19, 401-408 (2010).
31. Hughes, J.R., Russ, C.I., Arteaga, C.E. & Rennard, S.I. Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a cross-study analysis. Addict. Behav. 36, 1288-1291 (2011).
32. Swan, G.E. et al. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. Pharmacogenomics J. (2011); e-pub ahead of print 24 May 2011.
33. Patterson, F. et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther. 84, 320-325 (2008).
34. Becker, K.M., Rose, J.E. & Albino, A.P. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob. Res. 10, 1139-1148 (2008). (Pubitemid 352044699)
35. Ravva, P., Gastonguay, M.R., French, J.L., Tensfeldt, T.G. & Faessel, H.M. Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin. Pharmacol. Ther. 87, 336-344 (2010).
36. Faessel, H.M., Obach, R.S., Rollema, H., Ravva, P., Williams, K.E. & Burstein, A.H. Areview of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin. Pharmacokinet. 49, 799-816 (2010).
37. Hughes, J.R., Rennard, S.I., Fingar, J.R., Talbot, S.K., Callas, P.W. & Fagerstrom, K.O. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine Tob. Res. 13, 955-964 (2011).
38. World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects http://wma.net/en/30publications/ 10policies/b3(2008).
39. Carter, B.L. & Tiffany, S.T. The cue-availability paradigm: the effects of cigarette availability on cue reactivity in smokers. Exp. Clin. Psychopharmacol. 9, 183-190 (2001). (Pubitemid 32852319)
40. Hughes, J.R. & Hatsukami, D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 43, 289-294 (1986). (Pubitemid 16052281)
41. Westman, E., Levin, E. & Rose, J. Smoking while wearing the nicotine patch: is smoking satisfying or harmful. Clin Res 40, 871A (1992).
42. Rose, J.E. & Behm, F.M. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob. Res. 6, 523-532 (2004). (Pubitemid 38967541)
43. Stone, A.A., Shiffman, S. & Atienza, A. The Science of Real-Time Data Capture: Self-Reports in Health Research (Oxford University Press, NY, 2007).
44. Lee, J.H., Jones, P.G., Bybee, K. & O'Keefe, J.H. A longer course of varenicline therapy improves smoking cessation rates. Prev. Cardiol. 11, 210-214 (2008).
45. Huynh, H. & Feldt, L.S. Estimation of the Box correction for degrees of freedom from sample data in randomized block and split-plot designs. Journal of Educational and Behavioral Statistics 1, 69 (1976).